Clinical Trial

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX37 in patients with advanced/metastatic solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-28.
Status change: Active, Not Recruiting → Recruiting 2026-02-27
Trial Details
NCT Number NCT07274813
Lead Sponsor Shanghai Henlius Biotech
Conditions Advanced/Metastatic Solid Tumors, NSCLC
Enrollment 254 participants
Start Date 2025-12-29
Primary Completion 2027-03-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-03